In the MI model of rats, gene therapy of kallikrein can increase capillary density, reduce apoptosis, reduce endothelial dysfunction and improve cardiac function after MI (134), and the mechanism is possibly concerned with the kinin B2 receptor-Akt-GSK-3beta and VEGF signaling pathways (135). Here, KLK4 is linked to myocardial infarction.